News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

CEO and senior executives in Egetis Therapeutics acquire shares

August 26, 2021

Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, Kristina Sjöblom Nygren, CMO, and Henrik Krook, Vice President Commercial Operations, have acquired shares in the company.

Nicklas Westerholm has bought 10,225 additional shares, Kristina Sjöblom Nygren has bought 4,000 shares and Henrik Krook has bought 31,045 additional shares. Their respective total holdings now amount to 58,940, 6,000 and 140,000 shares in addition to warrants and employee stock options.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com